TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35183221

Group type: EXPERIMENTAL
Intervention: Radiotherapy interruption due to Spring Festival holidays
Number of subjects: 5035

Group type: EXPERIMENTAL
Intervention: Timing of radiotherapy interruption during Spring Festival
Number of subjects: 5035

Group type: EXPERIMENTAL
Intervention: Absence of concurrent chemotherapy (CC)
Number of subjects: 5035

Group type: EXPERIMENTAL
Intervention: Accumulated dose of cisplatin < 200 mg
Number of subjects: 5035
Study: 35183261

Group type: EXPERIMENTAL
Intervention: tDCS-enhanced inhibitory control training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation (control condition)
Number of subjects: 40
Study: 35183442

Group type: EXPERIMENTAL
Intervention: IFNγ-stimulated bone marrow-derived mesenchymal stromal cells (BM-MSCs) injected into the submandibular gland.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IFNγ-stimulated BM-MSCs
Number of subjects: 30
Study: 35183451

Group type: EXPERIMENTAL
Intervention: Temporary Gastric Electrical Stimulation (tGES)
Number of subjects: 1345
Study: 35183477

Group type: EXPERIMENTAL
Intervention: Progression of thoracic aortic calcium volume after 12.7 ± 2.7 months
Number of subjects: 0
Study: 35183478

Group type: EXPERIMENTAL
Intervention: AI-QCT analysis
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: AI-QCT evaluation
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: AI-QCT findings
Number of subjects: 303
Study: 35183775

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 329
Study: 35184142

Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) ≥150 mmHg and 10-year predicted ASCVD risk <20%
Number of subjects: 7426

Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) ≥150 mmHg and 10-year predicted ASCVD risk 20-34%
Number of subjects: 7426

Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) ≥150 mmHg and 10-year predicted ASCVD risk ≥35%
Number of subjects: 7426
Study: 35184256

Group type: EXPERIMENTAL
Intervention: DM1157
Number of subjects: 0
Study: 35184428

Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluations including clinical dementia rating-sum of boxes (CDR-SOB)
Number of subjects: 25
Study: 35184825

Group type: EXPERIMENTAL
Intervention: In-depth interviews and focus group discussions addressing social norms and child marriage
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Efforts to reduce child marriage through education and economic opportunities
Number of subjects: 20
Study: 35185515

Group type: EXPERIMENTAL
Intervention: Home-based transcranial direct current stimulation (tDCS) administered by study companions, 37 sessions over 12 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training program for study companions to administer tDCS remotely.
Number of subjects: 0
Study: 35185579

Group type: EXPERIMENTAL
Intervention: Jiangtang Tiaozhi Recipe
Number of subjects: 0
Study: 35185746

Group type: EXPERIMENTAL
Intervention: Digital Dance for PD (10-h weekly sessions)
Number of subjects: 23
Study: 35185883

Group type: EXPERIMENTAL
Intervention: IKKβ-matured, RNA-loaded dendritic cells
Number of subjects: 0
Study: 35185912

Group type: EXPERIMENTAL
Intervention: CXCL1 expression in mesothelial cells
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Peritoneal microvessel density
Number of subjects: 56
Study: 35186075

Group type: EXPERIMENTAL
Intervention: ECG247 Smart Heart Sensor
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard 12-lead ECG
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both systems (ECG247 Smart Heart Sensor and standard 12-lead ECG)
Number of subjects: 97
Study: 35186258

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-monthly (PP3M)
Number of subjects: 0
Study: 35186305

Group type: EXPERIMENTAL
Intervention: HBPT + case management
Number of subjects: 100

Group type: COMPARATOR
Intervention: HBPT + usual care
Number of subjects: 100
Study: 35186675

Group type: EXPERIMENTAL
Intervention: Combined metabolic surgery (gastric bypass) plus medical therapy (CSM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy alone (MTA)
Number of subjects: 0
Study: 35187036

Group type: EXPERIMENTAL
Intervention: DGA-conforming diet (DGAD) with 240 g/wk of salmon and albacore tuna
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical American diet (TAD)
Number of subjects: 0
Study: 35187107

Group type: EXPERIMENTAL
Intervention: Proteins involved in vascular processes (MYO and C-C-22)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Proteins involved in vascular processes (PS-3 and PAF-AH)
Number of subjects: 544
Study: 35187168

Group type: EXPERIMENTAL
Intervention: Passive simulated jogging device (JD) for 90 minutes per day for 7 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Passive simulated jogging device (JD)
Number of subjects: 21
Study: 35187383

Group type: EXPERIMENTAL
Intervention: letrozole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: intramuscular low-dose testosterone
Number of subjects: 28
Study: 35187395

Group type: EXPERIMENTAL
Intervention: Befriending intervention
Number of subjects: 0
Study: 35187396

Group type: EXPERIMENTAL
Intervention: Dietary phosphorus load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food matrix
Number of subjects: 0
Study: 35187490

Group type: EXPERIMENTAL
Intervention: Online palliative rehabilitation program
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Family caregivers' coping strategies
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Health professionals' coping strategies
Number of subjects: 16
Study: 35187671

Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (GE)
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Normal gastric emptying (GE)
Number of subjects: 1563
Study: 35187951

Group type: EXPERIMENTAL
Intervention: Palbociclib, Letrozole, and Venetoclax combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy with a CDK4/6 inhibitor (gold standard treatment)
Number of subjects: 0
Study: 35188473

Group type: EXPERIMENTAL
Intervention: Usual care plus LiveWell (smartphone-based self-management intervention)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study: 35188608

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study: 35188911

Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 1
Study: 35189157

Group type: EXPERIMENTAL
Intervention: 5 × 9 Gy prostate cancer SABR
Number of subjects: 219
Study: 35189168

Group type: EXPERIMENTAL
Intervention: hs-cTnI-Architect
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: ESC 0/1h-hs-cTnI-algorithms
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: hs-cTnI-Atellica
Number of subjects: 392
Study: 35189353

Group type: EXPERIMENTAL
Intervention: Adaptive pain calibration procedure with 24 heat trials
Number of subjects: 171
Study: 35189692

Group type: EXPERIMENTAL
Intervention: Social isolation (composite variable based on marital/partner status, religious ties, and community ties)
Number of subjects: 36457

Group type: EXPERIMENTAL
Intervention: Social isolation with depressive symptoms included in the model
Number of subjects: 36457

Group type: COMPARATOR
Intervention: Nonisolated women
Number of subjects: 36457
Study: 35189706

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2240
Study: 35189900

Group type: EXPERIMENTAL
Intervention: NLR (Neutrophil-to-Lymphocyte Ratio)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: COPD (Chronic Obstructive Pulmonary Disease)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 106
Study: 35190519

Group type: EXPERIMENTAL
Intervention: Apatinib plus temozolomide (temozolomide 300 mg on days 1-5 and apatinib 500 mg daily every 28-day cycle)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Apatinib plus temozolomide
Number of subjects: 29
Study: 35190653

Group type: EXPERIMENTAL
Intervention: Radium-223 treatment
Number of subjects: 1180
Study: 35190880

Group type: EXPERIMENTAL
Intervention: Congenital Heart Disease (CHD) group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Infants without CHD (Control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All infants
Number of subjects: 45
Study: 35191018

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg /1·5 mL subcutaneously at weeks 0, 1, 2, 4 and every 2 weeks thereafter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 10
Study: 35191329

Group type: EXPERIMENTAL
Intervention: Histamine H
Number of subjects: 0
Study: 35191428

Group type: EXPERIMENTAL
Intervention: CYAD-101 (NKG2D-based CAR T-cell therapy)
Number of subjects: 0
Study: 35191735

Group type: EXPERIMENTAL
Intervention: Transrectal US-guided biopsy with MRI fusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transrectal US-guided biopsy without MRI fusion
Number of subjects: 0
Study: 35191738

Group type: EXPERIMENTAL
Intervention: (4S)-4-(3-
Number of subjects: 0
Study: 35191860

Group type: EXPERIMENTAL
Intervention: Patients with MDD experiencing OCS
Number of subjects: 482
Study: 35192053

Group type: EXPERIMENTAL
Intervention: sintilimab + nab-paclitaxel + carboplatin (2-3 cycles before surgery)
Number of subjects: 20
Study: 35192550

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (90-minute treadmill run at 60% VO2max) in NWT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Acute aerobic exercise (90-minute treadmill run at 60% VO2max) in OWT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pre-exercise metabolite profile including FAHFAs, FFAs, and adenine intermediates
Number of subjects: 25
Study: 35192686

Group type: EXPERIMENTAL
Intervention: Inpatient chemotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Post-hospital discharge
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Antibiotic pressure reduction
Number of subjects: 52
Study: 35192703

Group type: EXPERIMENTAL
Intervention: Pain EASE program (tailored internet-based intervention)
Number of subjects: 58
Study: 35192798

Group type: EXPERIMENTAL
Intervention: Measured RMR (1552±319 kcal/d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Predicted RMR using McArdle-Katch (1652±233 kcal/d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Predicted RMR using Livingston (1677±230 kcal/d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Predicted RMR using Mifflin (1707±242 kcal/d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Predicted RMR using Institute of Medicine (2437±386 kcal/d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Predicted RMR (8 of 9 equations)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Appendicular lean mass correlation (r=0.64)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Total lean mass correlation (r=0.64)
Number of subjects: 71
Study: 35193124

Group type: EXPERIMENTAL
Intervention: Robotic control for wrist-hand rehabilitation after stroke
Number of subjects: 0
Study: 35193697

Group type: EXPERIMENTAL
Intervention: Fear of movement-related pain and avoidance behavior
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Negative expectancies towards recovery and work resumption, longer pain duration, and more severe pain before surgery
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Optimism and positive expectancies towards recovery and work resumption
Number of subjects: 300
Study: 35193705

Group type: EXPERIMENTAL
Intervention: Hybrid High-Intensity Interval Training (HIIT) using Functional Electrical Stimulation (FES) leg cycling and arm ski ergometer
Number of subjects: 8
Study: 35193825

Group type: EXPERIMENTAL
Intervention: Sibling cord blood cell infusion (12/12 HLA-matched)
Number of subjects: 12
Study: 35193905

Group type: EXPERIMENTAL
Intervention: Psychiatric treatment in the public health system of the Maule Region, Chile
Number of subjects: 0
Study: 35193933

Group type: EXPERIMENTAL
Intervention: ISA101 and nivolumab
Number of subjects: 24
Study: 35193932

Group type: EXPERIMENTAL
Intervention: Toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined with axitinib 5 mg orally two times per day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Toripalimab plus axitinib
Number of subjects: 29
Study: 35194110

Group type: EXPERIMENTAL
Intervention: Healthy active group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy sedentary group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary cardiovascular risk patients
Number of subjects: 0
Study: 35194187

Group type: EXPERIMENTAL
Intervention: HCMV infection (AD169, Towne, TB40E, VR1814 strains)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard-of-care genotoxic radio-chemotherapy
Number of subjects: 0
Study: 35194596

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35194723

Group type: EXPERIMENTAL
Intervention: Physical exercise habits
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interest in exercise program
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lifestyle change willingness
Number of subjects: 40
Study: 35194746

Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUC
Number of subjects: 82398

Group type: EXPERIMENTAL
Intervention: Copper IUC
Number of subjects: 82398

Group type: COMPARATOR
Intervention: Tubal ligation
Number of subjects: 82398
Study: 35194965

Group type: EXPERIMENTAL
Intervention: Muscle vesicles from ALS myotubes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Muscle vesicles from healthy myotubes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Anti-CD63 immuno-blocking of vesicle uptake
Number of subjects: 27
Study: 35195331

Group type: EXPERIMENTAL
Intervention: DK crush stenting technique
Number of subjects: 435
Study: 35195533

Group type: EXPERIMENTAL
Intervention: Modified Intermittent Fasting (MIF) for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular diet for 12 weeks
Number of subjects: 24
Study: 35195562

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with full dose systemic chemotherapy; SBRT dosing: 60 Gy in 3 fractions for peripheral tumors, 50 Gy in 5 fractions for central tumors, 40-50 Gy in 5 fractions for hilar/mediastinal lymph nodes; Chemotherapy: 4 cycles of pemetrexed and cisplatin or carboplatin and paclitaxel for nonsquamous histology; cisplatin and docetaxel or cisplatin and paclitaxel for squamous histology; SBRT given between chemotherapy cycles with a 7-day break.
Number of subjects: 22
Study: 35195837

Group type: EXPERIMENTAL
Intervention: Varlitinib combined with paclitaxel (300 mg twice daily intermittently dosed)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Varlitinib combined with paclitaxel and carboplatin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Varlitinib combined with paclitaxel ± carboplatin ± trastuzumab
Number of subjects: 37
Study: 35195881

Group type: EXPERIMENTAL
Intervention: Dacomitinib 30 mg (single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal hepatic function (control group)
Number of subjects: 0
Study: 35196021

Group type: EXPERIMENTAL
Intervention: Cytokine-induced memory-like (ML) NK cells stimulated with interleukin-12 (IL-12), IL-15, and IL-18.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced-intensity conditioning (RIC)
Number of subjects: 0
Study: 35196139

Group type: EXPERIMENTAL
Intervention: Vitamin D status measurement
Number of subjects: 0
Study: 35196153

Group type: EXPERIMENTAL
Intervention: VLBW children with poor social-emotional functioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: VLBW children with typical social-emotional functioning
Number of subjects: 0
Study: 35196370

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax (oral ibrutinib [420 mg/d]; oral venetoclax [5-week ramp-up to 400 mg/d])
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax
Number of subjects: 159
Study: 35196395

Group type: EXPERIMENTAL
Intervention: 15-min intravenous infusion of brivaracetam (up to 5 mg/kg/day, not exceeding 200 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bolus injection of brivaracetam (up to 5 mg/kg/day, not exceeding 200 mg/day)
Number of subjects: 50
Study: 35196653

Group type: EXPERIMENTAL
Intervention: Education-corrected cutoff scores
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: CERAD-nb total scores
Number of subjects: 2369

Group type: COMPARATOR
Intervention: Uncorrected scores
Number of subjects: 2369
Study: 35196871

Group type: EXPERIMENTAL
Intervention: Flecainide acetate inhalation solution (30 mg, 60 mg, 90 mg, 120 mg, and 120 mg with saccharin)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Flecainide acetate inhalation solution (120 mg with saccharin)
Number of subjects: 101
Study: 35197191

Group type: EXPERIMENTAL
Intervention: Insomnia severity
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Nightmare severity
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Nightmare frequency
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Time spent in Stage 1 sleep
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea-hypopnea
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sleep efficiency
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Total sleep time
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea-hypopnea index
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Clinically significant anger
Number of subjects: 93
Study: 35197359

Group type: EXPERIMENTAL
Intervention: Higher stages of memory impairment assessed with FCSRT
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: SOMI-3 and -4 stages
Number of subjects: 4484
Study: 35198584

Group type: EXPERIMENTAL
Intervention: Low Protein (LP) diet
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normocalorie/Normoprotein (NP) diet
Number of subjects: 35
Study: 35198648

Group type: EXPERIMENTAL
Intervention: Coinfections (bacterial, viral, fungal)
Number of subjects: 8765

Group type: EXPERIMENTAL
Intervention: Tocilizumab administration
Number of subjects: 8765

Group type: EXPERIMENTAL
Intervention: High neutrophil count and C-reactive protein
Number of subjects: 8765

Group type: EXPERIMENTAL
Intervention: High or low neutrophil count
Number of subjects: 8765
Study: 35198727

Group type: EXPERIMENTAL
Intervention: SCOPE-CLI study intervention (observational registry)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 1, 2, 6, and 12 months
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Capture of hospitalizations, interventions, and outcomes for 12 months
Number of subjects: 816
Study: 35199226

Group type: EXPERIMENTAL
Intervention: ECTS patients
Number of subjects: 28
Study: 35199231

Group type: EXPERIMENTAL
Intervention: High anti-HPV16 L1 antibody titers
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: HPV16 viral load
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: HPV16 DNA integration
Number of subjects: 362
Study: 35199492

Group type: EXPERIMENTAL
Intervention: Curative radiotherapy
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (monotherapy)
Number of subjects: 401

Group type: COMPARATOR
Intervention: No prophylactic measures
Number of subjects: 401
Study: 35199944

Group type: EXPERIMENTAL
Intervention: Screening for hypertension (ever having had a BP measurement)
Number of subjects: 2737

Group type: EXPERIMENTAL
Intervention: Diagnosis of hypertension (previously informed of a HTN diagnosis)
Number of subjects: 2737

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension (having taken antihypertensives in the past 2 weeks)
Number of subjects: 2737

Group type: EXPERIMENTAL
Intervention: Control of hypertension (taking antihypertensives and having BP < 140/90 mmHg)
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Obesity (BMI ≥ 30)
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Secondary or higher education
Number of subjects: 2737
Study: 35200153

Group type: EXPERIMENTAL
Intervention: Online Peer Support Community (OPSC) intervention with Hispanic Spanish-speaking peer facilitators
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 50
Study: 35200196

Group type: EXPERIMENTAL
Intervention: Prone ventilation (n=24 patients)
Number of subjects: 50
Study: 35200588

Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor
Number of subjects: 242
Study: 35201306

Group type: EXPERIMENTAL
Intervention: ACP video decision aids and clinician communication intervention
Number of subjects: 14107
Study: 35201607

Group type: COMPARATOR
Intervention: Extended-release methylphenidate
Number of subjects: 5066
Study: 35201621

Group type: EXPERIMENTAL
Intervention: Mifamurtide combined with high-dose ifosfamide (HDIFO) for poor responders (PRs) after high-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively.
Number of subjects: 194

Group type: COMPARATOR
Intervention: High-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively.
Number of subjects: 194
Study: 35203047

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 130

Group type: COMPARATOR
Intervention: Actual thickness
Number of subjects: 130
Study: 35203258

Group type: EXPERIMENTAL
Intervention: miRNA biomarkers and relevant SNPs implementation in clinical setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative therapeutic schemes and drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miRNA-gene networks and genomic signatures analysis
Number of subjects: 0
Study: 35203321

Group type: EXPERIMENTAL
Intervention: Osteopontin (OPN) levels in patients with low cardiovascular risk
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Neutrophil-related biomarkers
Number of subjects: 544
Study: 35203547

Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 282

Group type: COMPARATOR
Intervention: AZD1222
Number of subjects: 282
Study: 35203750

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQs)
Number of subjects: 0
Study: 35204237

Group type: EXPERIMENTAL
Intervention: HD patients who survived (HD-A, n=51)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HD patients who died (HD-D, n=20)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy people (control group, n=32)
Number of subjects: 71
Study: 35204557

Group type: EXPERIMENTAL
Intervention: Apixaban (PROTECT-AR study)
Number of subjects: 157

Group type: COMPARATOR
Intervention: PhyS C
Number of subjects: 157

Group type: COMPARATOR
Intervention: PhyS D
Number of subjects: 157

Group type: COMPARATOR
Intervention: AnatC II
Number of subjects: 157

Group type: COMPARATOR
Intervention: AnatC III
Number of subjects: 157